Biomarkers at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

18 organizations at EBF 2026 present work in biomarkers and context of use: 13 CROs and suppliers and 5 drug developers. Between them they bring 34 presentations to the program. Most represented: Roche (9 on the program), GSK (4 on the program), Nuvisan (3 on the program). 15 of them have their own page in this guide. As of Oct 13, 2026.

All 63 organizations at EBF 2026 →

Showing 1–14 of 18 organizations

Organization	EBF 2026 Attendance
Roche Basel, Switzerland
roche.com Pharma Pharmaceutical and diagnostics group developing medicines in oncology, immunology, neuroscience and ophthalmology, alongside its Roche Diagnostics business.	Talk Tue Nov 17 11:30–11:50am Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Clinical Speed meets GLP Rigor: Upgrading an IVD Immunoanalyzer for High-Throughput PK/PD Analysis in a Bioanalytical Laboratory - Lessons Learnt Automation & AI · Ligand binding Talk Tue Nov 17 2:40–3pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics LC-MS Bioanalysis of Lipid Conjugated siRNAs: Analytical Challenges and Novel Approaches New modalities · LC–MS Talk Tue Nov 17 5:20–5:40pm Part of Session 7: BM CoU in practice Navigating Soluble Biomarker Complexity: Challenges, Assay Strategy, and Case Studies Biomarkers Talk Wed Nov 18 9–9:20am Part of Session 10: Bioanalysis Beyond Conventional Matrices From First-in-Human to Multi-Site Trials: Practical Bioanalytical Strategies to Preserve CSF Pharmacokinetic Data for Highly Adsorptive Molecules Sampling Talk Wed Nov 18 9:20–9:40am Part of Session 12: Assay life cycle Assay Lifecycle in Practice: Strategic Stewardship, Change Control, and Revalidation Case Studies Regulation Talk Wed Nov 18 9:40–10am Part of Session 10: Bioanalysis Beyond Conventional Matrices Operationalizing Unstable Biomarkers: How Biosample Operations and Bioanalysis Enable Successful Scale-Up from Single-Site to Multi-Site Clinical Trials Biomarkers · Sampling Talk Wed Nov 18 5–5:20pm Part of Workshop 10: ADA - Adaptive Tier Overcoming the 3-Tier ADA Testing Paradigm via Mechanistic Assay Understanding Immunogenicity Talk Thu Nov 19 9:20–9:40am Part of Session 16: Protein MS tech 1 A Multiplexed LC-MS/MS Strategy for the Simultaneous Quantification of a Transgene Protein and its Endogenous Counterpart in a Gene Therapy Program. LC–MS Talk Thu Nov 19 11:30–11:50am Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Navigating High-Plex Profiling and Targeted Quantification in Drug Development Biomarkers
GSK London, UK
gsk.com Pharma Pharmaceutical company developing vaccines and medicines for infectious diseases, HIV, respiratory and immune-mediated diseases, and oncology.	Talk Tue Nov 17 12:10–12:30pm Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Automation Innovations Drive Efficiencies in Flow Cytometry Clinical Sample Testing Automation & AI · Cell-based Talk Tue Nov 17 4:40–5pm Part of Session 8: Pharma CRO Lessons Learned During In-Licensing Talk Wed Nov 18 11:20–11:40am Part of Session 13: BioA Clinic It’s not your assay, it’s us: reappraising the CoU in response to extra-analytical factors Biomarkers Talk Thu Nov 19 9:40–10am Part of Session 15: Flow Operationalising high-parameter flow cytometry for large-scale clinical research Cell-based
Nuvisan Neu-Ulm, Germany	◇Sponsor
nuvisan.com Bioanalytical CROsSponsor CRO offering drug discovery, bioanalysis, clinical pharmacology and CMC services.	Talk Tue Nov 17 4:20–4:40pm Part of Session 7: BM CoU in practice Target Engagement Biomarkers: Context-of-Use Driven Assay Selection Biomarkers Talk Thu Nov 19 10–10:20am Part of Session 16: Protein MS tech 1 Overcoming High Soluble Target Interference in Drug Quantification: A Hybrid Immunocapture LC-MS/MS Approach for Clinical Bioanalysis LC–MS Talk Thu Nov 19 12:10–12:30pm Part of Session 18: Connecting Metabolism, Exposure and Multi-Omics Challenges and prospects of targeted metabolomics kits validation LC–MS · Biomarkers
QPS Newark, Delaware	◇Sponsor
qps.com Bioanalytical CROsSponsor CRO specialising in regulated bioanalysis, DMPK, toxicology and clinical research.	Talk Tue Nov 17 2:20–2:40pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics M10 Compliant Quan–Qual Analysis of Parent Oligonucleotides and Metabolites Using a Next-Generation QTOF Platform New modalities · LC–MS Talk Tue Nov 17 5–5:20pm Part of Session 7: BM CoU in practice Best Practices of Performing Parallelism in Biomarker Assays: A CRO Perspective Biomarkers Talk Wed Nov 18 9:40–10am Part of Session 12: Assay life cycle Challenges during implementation of new reagent lots Ligand binding
Ardena Ghent, Belgium	◇Sponsor
ardena.com Bioanalytical CROsSponsor Drug development CDMO and CRO offering formulation, manufacturing and regulated bioanalysis services.	Talk Tue Nov 17 11:50am–12:10pm Part of Session 3: Vaccines Vaccine Ligand-Binding Assays for Clinical Sample Analysis: Qualification vs. Validation - A Fit-for-Purpose Approach to Dilution Series and Cut-Point Selection Vaccines · Ligand binding Talk Wed Nov 18 12–12:20pm Part of Session 13: BioA Clinic Analytical Challenges in Sphingolipid Quantification: Enabling Biomarker Discovery in Lysosomal and Neurodegenerative Disorders Biomarkers · LC–MS
Labcorp Burlington, North Carolina	◇Sponsor
labcorp.com Bioanalytical CROsSponsor Laboratory services company whose drug development unit runs central lab, bioanalysis and early development services.	Talk Tue Nov 17 2:40–3pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows From Collection to Analysis: Evaluating Patient-Centric Dried Blood Microsampling Technologies for Regulated Bioanalysis Sampling Talk Tue Nov 17 5:20–5:40pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR Measuring Biological Response Using RT-qPCR: A Bioanalytical Perspective on Relative Gene Expression PCR · Biomarkers
argenx
argenx.com Biotech Immunology biotech whose antibody efgartigimod treats generalized myasthenia gravis and other autoimmune diseases.	Talk Tue Nov 17 5:40–6pm Part of Session 7: BM CoU in practice From qualitative detection to quantitative insight: repurposing a diagnostic assay into a fit-for-purpose semi-quantitative titer assay as measure of treatment response Biomarkers Talk Wed Nov 18 11:40am–12pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 A streamlined ADA testing strategy to assess the clinical immunogenicity of a biological drug entering clinical development Immunogenicity
Aliri Colorado Springs, Colorado	◇Sponsor
aliribio.com Bioanalytical CROsSponsor Bioanalytical CRO formed from Pyxant Labs and ImaBiotech, offering regulated LC–MS and ligand-binding bioanalysis and spatial bioanalysis, with labs in the US and France.	Talk Tue Nov 17 4:40–5pm Part of Session 7: BM CoU in practice When “How Much?” Is Not Enough: Adding the “Where” to Bioanalysis Biomarkers
Evotec Hamburg, Germany	◇Sponsor
evotec.com Bioanalytical CROsSponsor Drug discovery and development partner offering research, preclinical, bioanalysis and manufacturing services, including at its Aptuit site in Verona.	Talk Thu Nov 19 12:10–12:30pm Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Next-Generation Ultrasensitive Protein Detection in Huntington's Disease: from SMC™ to NULISA™ Technology Biomarkers
KCAS Bio Olathe, Kansas	◇Sponsor
kcasbio.com Bioanalytical CROsSponsor Bioanalytical and biomarker CRO running LC–MS, ligand-binding, flow cytometry and immunogenicity assays for drug developers.	Talk Thu Nov 19 12:30–12:50pm Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Combining versatility and ultrasensitivity with the NULISA technology Biomarkers
Mercodia Uppsala, Sweden	◇Sponsor
mercodia.com Instruments, reagents & softwareSponsor Makes immunoassay kits for metabolic and other biomarkers and runs bioanalytical assay services.	Talk Wed Nov 18 10:20–10:40am Part of Session 12: Assay life cycle Lifecycle Management of a Clinical PK Assay Through Change Control, Investigation, Optimization and Revalidation Ligand binding · Regulation
Microcoat Biotechnologie Bernried, Germany	◇Sponsor
microcoat.de Bioanalytical CROsSponsor Contract lab and manufacturer offering assay development, bioanalytical testing and immunoassay component manufacturing.	Talk Thu Nov 19 11:50am–12:10pm Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Next-Generation Ultrasensitive Biomarker Testing: Enabling Scalable Blood-Based Biomarker Strategies for Global Clinical Trials Biomarkers
Synexa Life Sciences Cape Town, South Africa	◇Sponsor
synexagroup.com Bioanalytical CROsSponsor Bioanalytical and biomarker lab running ligand-binding, flow cytometry and LC–MS assays for drug developers.	Talk Tue Nov 17 11:30–11:50am Part of Session 3: Vaccines When One Calibration Source Must Fit Eight Antigens: Lessons from Convalescent and Vaccinated Serum to Evaluate Vaccine-Induced Antibody Responses Vaccines
CellCarta Montreal, Canada
cellcarta.com Bioanalytical CROs Specialty lab running biomarker assays for clinical trials, including flow cytometry, immunohistochemistry, genomics and proteomics.	Talk Wed Nov 18 11:40am–12pm Part of Session 13: BioA Clinic Keeping It Soluble: A Quantitative Biomarker Comparison of BCMA and M-Protein by Mass Spectrometry in Multiple Myeloma Biomarkers · LC–MS